Fjarde Ap Fonden Nektar Therapeutics Transaction History

Fjarde Ap Fonden

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$15.87 - $23.12 $353,599 - $515,136	-22,281 Closed	0 $0
Q3 2019 Oct 31, 2019	SELL	$16.91 - $36.27 $248,577 - $533,169	-14,700 Reduced 39.75%	22,281 $406,000
Q2 2019 Jul 17, 2019	SELL	$31.0 - $36.3 $372,000 - $435,599	-12,000 Reduced 24.5%	36,981 $1.32 Million
Q1 2019 Apr 29, 2019	BUY	$31.58 - $46.35 $271,903 - $399,073	8,610 Added 21.33%	48,981 $1.65 Million
Q4 2018 Jan 31, 2019	SELL	$30.43 - $56.65 $255,612 - $475,860	-8,400 Reduced 17.22%	40,371 $1.33 Million
Q3 2018 Nov 09, 2018	BUY	$46.46 - $68.49 $129,484 - $190,881	2,787 Added 6.06%	48,771 $2.97 Million
Q2 2018 Jul 12, 2018	BUY	$46.25 - $104.45 $2.13 Million - $4.8 Million	45,984 New	45,984 $2.25 Million

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $191M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.